Program
ABBV-722
A development code.
In AbbVie's pipeline, LPAR1
. Its studies are mostly in Scleroderma, Systemic · Arthritis, Rheumatoid, led by AbbVie.
Furthest: phase 3, since Oct 23, 20268 company-led studies, 2 open or runningNext primary completion: Jul 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 82 open or running | phase 3since Oct 23, 2026 | Oct 29, 2024 | Jul 2029phase 2 · NCT07904754 |
- Named in AbbVie’s own pipeline as
ABBV-722
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2024First study: phase 1 study in Healthy VolunteerFirst studyNCT06673238 · 95 enrolled · United States
- Jan 15, 2026Phase 1 study in Healthy VolunteersNCT07361367 · 11 enrolled · United States
- Feb 17, 2026Phase 1 study in Healthy VolunteerNCT07425899 · 16 enrolled · United States
- Mar 26, 2026Phase 1 study in Healthy VolunteerNCT07502417 · 15 enrolled · United States
- Apr 28, 2026Phase 1 study in Healthy VolunteersNCT07567781 · 12 enrolled · United States
- May 7, 2026Phase 1 study in Healthy VolunteersNCT07599761 · 12 enrolled · United States
- Oct 23, 2026Phase 3 study in Scleroderma, SystemicPhase 3 reachedNCT07933211 · 580 planned
- Oct 23, 2026Phase 2 study in Arthritis, RheumatoidNCT07904754 · 250 planned
Ahead
- Jul 2029Primary completion: phase 2 study in Arthritis, RheumatoidNCT07904754
- Jun 2035Primary completion: phase 3 study in Scleroderma, SystemicNCT07933211
TargetBeta
“LPAR1”the company's pipeline, read by Claude · source
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933211Scleroderma, Systemic | 3 | Not yet recruiting | Jun 2035 | 580 |
| NCT07904754Arthritis, Rheumatoid | 2 | Not yet recruiting | Jul 2029 | 250 |
| NCT07599761Healthy Volunteers · United States | 1 | Completed | Sep 3, 2026 | 12 |
| NCT07567781Healthy Volunteers · United States | 1 | Completed | Jul 21, 2026 | 12 |
| NCT07502417Healthy Volunteer · United States | 1 | Completed | Jul 2, 2026 | 15 |
| NCT07425899Healthy Volunteer · United States | 1 | Completed | Jun 5, 2026 | 16 |
| NCT07361367Healthy Volunteers · United States | 1 | Completed | Mar 23, 2026 | 11 |
| NCT06673238Healthy Volunteer · United States | 1 | Completed | Jun 25, 2026 | 95 |
How it is read
Names in the registry
- “ABBV-722”, 8 entries
Codes read as this program: ABBV722.
Conditions, from the studies’ own filings
- Scleroderma, Systemic, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.